163 related articles for article (PubMed ID: 21079521)
1. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.
Brahmer JR; Dahlberg SE; Gray RJ; Schiller JH; Perry MC; Sandler A; Johnson DH
J Thorac Oncol; 2011 Jan; 6(1):103-8. PubMed ID: 21079521
[TBL] [Abstract][Full Text] [Related]
2. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler AB; Schiller JH; Johnson DH;
J Clin Oncol; 2008 Jan; 26(1):60-5. PubMed ID: 18165641
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.
Sandler A; Yi J; Dahlberg S; Kolb MM; Wang L; Hambleton J; Schiller J; Johnson DH
J Thorac Oncol; 2010 Sep; 5(9):1416-23. PubMed ID: 20686429
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Socinski MA; Scappaticci FA; Samant M; Kolb MM; Kozloff MF
J Thorac Oncol; 2010 Mar; 5(3):354-60. PubMed ID: 20032789
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
7. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Hoang T; Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
J Thorac Oncol; 2012 Sep; 7(9):1361-8. PubMed ID: 22843087
[TBL] [Abstract][Full Text] [Related]
8. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
J Clin Oncol; 2010 Feb; 28(6):949-54. PubMed ID: 20085937
[TBL] [Abstract][Full Text] [Related]
9. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
10. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
Clément-Duchêne C; Krupitskaya Y; Ganjoo K; Lavori P; McMillan A; Kumar A; Zhao G; Padda S; Zhou L; Pedro-Salcedo MS; Colevas AD; Wakelee HA
J Thorac Oncol; 2010 Nov; 5(11):1821-5. PubMed ID: 20881641
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
[TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
14. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Dowlati A; Gray R; Sandler AB; Schiller JH; Johnson DH
Clin Cancer Res; 2008 Mar; 14(5):1407-12. PubMed ID: 18316562
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
16. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
Kim ES; Moon J; Herbst RS; Redman MW; Dakhil SR; Velasco MR; Hirsch FR; Mack PC; Kelly K; Heymach JV; Gandara DR
J Thorac Oncol; 2013 Dec; 8(12):1519-28. PubMed ID: 24189513
[TBL] [Abstract][Full Text] [Related]
19. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]